<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">MNyY5CmwjDXQsnk99fVnkJw</article-id>
      <article-id pub-id-type="other">00011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2009000500011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(09)09200511</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2009000500011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Variabilidade da frequ&#234;ncia card&#237;aca em pacientes com anemia ferropriva</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Tuncer</surname>
            <given-names>Mustafa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gunes</surname>
            <given-names>Yilmaz</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guntekin</surname>
            <given-names>Unal</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gumrukcuoglu</surname>
            <given-names>Hasan Ali</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eryonucu</surname>
            <given-names>Beyhan</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guler</surname>
            <given-names>Niyazi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dilek</surname>
            <given-names>Imdat</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Demir</surname>
            <given-names>Cengiz</given-names>
          </name>
          <xref ref-type="aff" rid="aff02"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Van</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Yuzuncu Yil University</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Departamento de Cardiologia</institution>
        <country country="TR">Turkey</country>
      </aff>
      <aff id="aff02">
        <addr-line>
          <named-content content-type="city">Van</named-content>
          <named-content content-type="state"/>
        </addr-line>
        <institution content-type="orgname">Yuzuncu Yil University</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Departamento de Hematologia</institution>
        <country country="TR">Turkey</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>05</month>
        <year>2009</year>
      </pub-date>
      <volume>92</volume>
      <issue>5</issue>
      <fpage>400</fpage>
      <lpage>403</lpage>
      <history>
        <date date-type="rev-recd">
          <day>28</day>
          <month>03</month>
          <year>2008</year>
        </date>
        <date date-type="received">
          <day>19</day>
          <month>11</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>07</day>
          <month>04</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A variabilidade da frequ&#234;ncia card&#237;aca (VFC) est&#225; associada com aumento do fator de risco card&#237;aco em v&#225;rias condi&#231;&#245;es. As concentra&#231;&#245;es de ferro apresentadas por um indiv&#237;duo podem ter um papel importante na sa&#250;de cardiovascular. OBJETIVO: Avaliar a VFC em pacientes com anemia ferropriva. M&#201;TODOS: Vinte e tr&#234;s pacientes com anemia ferropriva (hemoglobina (Hb) m&#233;dia = 8,6&#177;2,2 g/dl) e 10 indiv&#237;duos saud&#225;veis ( Hb m&#233;dia = 13,9&#177;1,2 g/dl) foram avaliados atrav&#233;s de monitoramento ambulatorial por 24 horas (Sistema Holter) durante estadia hospitalar com atividade f&#237;sica limitada. RESULTADOS: Embora a frequ&#234;ncia card&#237;aca (FC) m&#233;dia tenha sido significantemente mais alta em pacientes com anemia, n&#227;o houve diferen&#231;a significativa em rela&#231;&#227;o aos par&#226;metros da VFC quando comparados ao grupo saud&#225;vel. CONCLUS&#195;O: N&#227;o h&#225; diferen&#231;a significativa nos par&#226;metros da VFC entre pacientes com anemia ferropriva e indiv&#237;duos saud&#225;veis.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Frequ&#234;ncia card&#237;aca</kwd>
        <kwd>anemia ferropriva</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>20</day>
        <month>07</month>
        <year>2009</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>ARTIGO ORIGINAL </p>
    <p> HOLTER/ LOOPER</p>
    <p>
      <bold>Variabilidade da frequ&#234;ncia card&#237;aca em pacientes com anemia ferropriva</bold>
    </p>
    <p>
      <bold>Mustafa Tuncer<sup>I</sup>; Yilmaz Gunes<sup>I</sup>; Unal Guntekin<sup>I</sup>; Hasan Ali Gumrukcuoglu<sup>I</sup>; Beyhan Eryonucu<sup>I</sup>; Niyazi Guler<sup>I</sup>; Imdat Dilek<sup>II</sup>; Cengiz Demir<sup>II</sup></bold>
    </p>
    <p><sup>I</sup>Universidade Yuzunci Yil, Faculdade de Medicina, Departamento de Cardiologia, Van - Turquia </p>
    <p><sup>II</sup>Universidade Yuzunci Yil, Faculdade de Medicina, Departamento de Hematologia, Van - Turquia</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> A variabilidade da frequ&#234;ncia card&#237;aca (VFC) est&#225; associada com aumento do fator de risco card&#237;aco em v&#225;rias condi&#231;&#245;es. As concentra&#231;&#245;es de ferro apresentadas por um indiv&#237;duo podem ter um papel importante na sa&#250;de cardiovascular. </p>
    <p><bold>OBJETIVO: </bold> Avaliar a VFC em pacientes com anemia ferropriva. </p>
    <p><bold>M&#201;TODOS: </bold> Vinte e tr&#234;s pacientes com anemia ferropriva (hemoglobina (Hb) m&#233;dia = 8,6&#177;2,2 g/dl) e 10 indiv&#237;duos saud&#225;veis ( Hb m&#233;dia = 13,9&#177;1,2 g/dl) foram avaliados atrav&#233;s de monitoramento ambulatorial por 24 horas (Sistema Holter) durante estadia hospitalar com atividade f&#237;sica limitada. </p>
    <p><bold>RESULTADOS: </bold> Embora a frequ&#234;ncia card&#237;aca (FC) m&#233;dia tenha sido significantemente mais alta em pacientes com anemia, n&#227;o houve diferen&#231;a significativa em rela&#231;&#227;o aos par&#226;metros da VFC quando comparados ao grupo saud&#225;vel. </p>
    <p><bold>CONCLUS&#195;O: </bold> N&#227;o h&#225; diferen&#231;a significativa nos par&#226;metros da VFC entre pacientes com anemia ferropriva e indiv&#237;duos saud&#225;veis. </p>
    <p><bold>Palavras-chave: </bold> Frequ&#234;ncia card&#237;aca, anemia ferropriva.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A anemia &#233; um fator de risco independente para resultados cardiovasculares adversos em pacientes com doen&#231;a renal<sup>1</sup> e possivelmente na popula&#231;&#227;o em geral<sup>2</sup>. Uma diminui&#231;&#227;o na variabilidade da frequ&#234;ncia card&#237;aca (VFC) est&#225; associada com aumento da mortalidade e morbidade em v&#225;rias formas de doen&#231;a card&#237;aca, incluindo infarto do mioc&#225;rdio, cardiomiopatia, insufici&#234;ncia card&#237;aca congestiva (ICC) e regurgita&#231;&#227;o mitral cr&#244;nica<sup>3-7</sup>.</p>
    <p>Os n&#237;veis de ferro s&#233;rico de um indiv&#237;duo podem ter um papel importante na sa&#250;de cardiovascular, considerando que o excesso ou a defici&#234;ncia de ferro podem levar a problemas significativos<sup>8</sup>. J&#225; foi sugerido que a anemia est&#225; associada com baixa VFC em pacientes ambulatoriais com doen&#231;a card&#237;aca coronariana est&#225;vel e que a baixa VFC poderia potencialmente mediar a associa&#231;&#227;o da anemia com aumento do risco cardiaco<sup>9</sup>. A anemia e sua associa&#231;&#227;o com VFC t&#234;m sido estudadas em v&#225;rios tipos de anemia, tais como talassemia<sup>10</sup>, defici&#234;ncia de vitamina B<sub>12</sub> e anemia megalobl&#225;stca<sup>11</sup>, e tra&#231;o falciforme<sup>12</sup>.</p>
    <p>O objetivo do presente estudo foi estudar a associa&#231;&#227;o entre par&#226;metros de VFC e anemia ferropriva.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Hemograma completo, esfrega&#231;o de sangue perif&#233;rico, ferritina s&#233;rica, ferro s&#233;rico, capacidade de liga&#231;&#227;o do ferro e satura&#231;&#227;o de transferrina foram examinados. O diagn&#243;stico de anemia ferropriva foi estabelecida como n&#237;veis de hemoglobina &lt; 12 g/dl em mulheres e &lt; 13 g/dl em homens, ferritina s&#233;rica &lt; 12 ng/ml, valores de volume corpuscular m&#233;dio (VCM) e concentra&#231;&#227;o m&#233;dia de hemoglobina corpuscular (CMHC) abaixo da faixa normal (83 a 97 fl e 32 a 36 g/dl, respectivamente)<sup>13</sup>.</p>
    <p>Com um n&#237;vel alfa de 0,05 e um poder de teste de 0,80, um tamanho de amostra de 32 participantes foi considerado adequado para definir uma diferen&#231;a de 15 ms em VFC entre os grupos. Um total de 23 pacientes hospitalizados diagnosticados como tendo anemia ferropriva [hemoglobina (Hb) m&#233;dia: 8,6&#177;2,2 g/dl] e dez pessoas saud&#225;veis foram inclu&#237;das no estudo. Todos os pacientes foram submetidos &#224; ecocardiografia transtor&#225;cica. Pacientes com sangramento agudo, malignidades, com sangramento cr&#244;nico conhecido, talassemia, doen&#231;a falciforme, doen&#231;a card&#237;aca estrutural, diabete, hipertens&#227;o, insufici&#234;ncia renal, hipo ou hipertireoidismo, ou qualquer outra doen&#231;a sist&#234;mica foram exclu&#237;dos do estudo. Todos os pacientes assinaram o termo de consentimento livre e informado e o estudo foi aprovado pelo Comit&#234; de &#201;tica do hospital.</p>
    <p>
      <bold>An&#225;lise da variabilidade de frequ&#234;ncia card&#237;aca</bold>
    </p>
    <p>Monitoriza&#231;&#227;o ambulatorial eletrocardiogr&#225;fica de 24 horas pelo sistema Holter foi realizada usando um equipamento gravador Del Mar Avionics 483 de 3 canais (<italic>Del Mar Medical Systems</italic>; Irvine, CA). Os registros foram analisados com um software especial (<italic>Del Mar Holter Analysis System; Del Mar Medical Systems</italic>). Todos os registros foram visualmente examinados e lidos manualmente para verificar a classifica&#231;&#227;o do batimento por um cardiologista com experi&#234;ncia. Batimentos anormais e &#225;reas de artefato foram automaticamente e manualmente identificados e exclu&#237;dos da an&#225;lise. Al&#233;m disso, os intervalos normal-a-normal (NN) verdadeiros mais longos e mais curtos foram identificados para cada registro a fim de excluir todos os batimentos fora dessa faixa da an&#225;lise de VFC. Os intervalos dentro da faixa foram cuidadosamente editados.</p>
    <p>Os seguintes par&#226;metros foram usados na avalia&#231;&#227;o da VFC no dom&#237;nio tempo:</p>
    <p>1) Desvio padr&#227;o (DP) de todos os intervalos NN (DPNN);</p>
    <p>2) DP da m&#233;dia de todos os intervalos NN em todos os segmentos, de 5 minutos consecutivos do total gravado (DPTNN) [milissegundos];</p>
    <p>3) valor quadr&#225;tico m&#233;dio das diferen&#231;as entre intervalos NN adjacentes (VQMDP) [milissegundos];</p>
    <p>4) m&#233;dia do desvio padr&#227;o em todos os intervalos de 5 minutos (MVFC) [milissegundos]; e</p>
    <p>5) desvio padr&#227;o em todos os intervalos de 5 minutos (DPVFC) [milissegundos].</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>Os resultados s&#227;o expressos em m&#233;dias e DP. Usando o software SPSS vers&#227;o 10.0, os dados dos grupos foram comparados atrav&#233;s do teste <italic>t</italic> de Student para vari&#225;veis cont&#237;nuas, teste do Qui-quadrado para vari&#225;veis dicot&#244;micas e Teste U de Mann-Whitney para vari&#225;veis sem distribui&#231;&#227;o normal. Um p bicaudal &lt; 0,05 foi considerado significante.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>As caracter&#237;sticas cl&#237;nicas do Holter de 24 horas da popula&#231;&#227;o estudada est&#227;o resumidas nas <xref ref-type="table" rid="t1">Tabelas 1</xref> e <xref ref-type="table" rid="t2">2</xref>. Todos os pacientes estavam em ritmo sinusal durante os registros. Nenhuma altera&#231;&#227;o de segmento ST foi registrada na popula&#231;&#227;o em geral. N&#227;o foram observadas patologias no exame ecocardiogr&#225;fico, exceto por leve regurgita&#231;&#227;o valvar dentro dos limites normais. A frequ&#234;ncia card&#237;aca (FC) m&#233;dia era significantemente mais alta em pacientes an&#234;micos quando comparados ao grupo controle (84,4&#177;22,4 bpm vs. 72,6&#177;13,2 bpm; p=0,005). N&#227;o houve diferen&#231;a significativa entre o grupo saud&#225;vel e os pacientes com defici&#234;ncia de ferro em rela&#231;&#227;o aos par&#226;metros de VFC.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt01.jpg"/></table-wrap>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt02.jpg"/></table-wrap>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>H&#225; um aumento das evid&#234;ncias de que a anemia contribui para a doen&#231;a card&#237;aca e morte<sup>14,15</sup>. Em pacientes com doen&#231;a renal cr&#244;nica, por exemplo, a anemia &#233; um fator de risco independente para o desenvolvimento de doen&#231;a cardiovascular<sup>1</sup>. Em pacientes com insufici&#234;ncia card&#237;aca (IC), a anemia est&#225; associada com aumento na morbidade<sup>7</sup>.</p>
    <p>Os registros de monitoriza&#231;&#227;o por Holter t&#234;m um papel essencial na identifica&#231;&#227;o de arritmias; sua amplamente dispon&#237;vel associa&#231;&#227;o com a an&#225;lise da VFC fornece informa&#231;&#245;es sobre as influ&#234;ncias do sistema nervoso aut&#244;nomo (SNA) e balan&#231;o simp&#225;tico-vagal. A VFC &#233; um m&#233;todo que determina os efeitos do SNA sobre o cora&#231;&#227;o e as mudan&#231;as espont&#226;neas na frequ&#234;ncia card&#237;aca. Uma diminui&#231;&#227;o na variabilidade da frequ&#234;ncia card&#237;aca reflete uma disfun&#231;&#227;o auton&#244;mica. A VFC diminui ap&#243;s IM e em neuropatia diab&#233;tica e IC. Atualmente, a VFC &#233; considerada um preditor de parada card&#237;aca s&#250;bita e arritmias<sup>3-6</sup>.</p>
    <p>A defici&#234;ncia de ferro &#233; a defici&#234;ncia nutricional mais comum em regi&#245;es desenvolvidas e em desenvolvimento do mundo. A resposta fisiol&#243;gica &#224; anemia &#233; um aumento compensat&#243;rio no d&#233;bito card&#237;aco atrav&#233;s de aumentos no volume de sangue, pr&#233;-carga, FC e volume de derrame, junto com uma diminui&#231;&#227;o na p&#243;s-carga. Dessa forma, o aumento na atividade simp&#225;tica, que se reflete como palpita&#231;&#227;o e taquicardia, &#233; freq&#252;ente em pacientes com anemia<sup>13</sup>.</p>
    <p>Um resultado extremo da defici&#234;ncia de ferro &#233; a cardiomiopatia. A patog&#234;nese da cardiomiopatia associada com anemia ainda n&#227;o foi constatada. V&#225;rias hip&#243;teses t&#234;m sido propostas para explicar como a anemia ferropriva causa a cardiomiopatia. Tem sido sugerido que, como em outros tipos de IC, a insufici&#234;ncia card&#237;aca de alto d&#233;bito seja dirigida por um aumento cont&#237;nuo da atividade nervosa simp&#225;tica. A fim de testar essa hip&#243;tese, um estudo utilizou beta-bloqueio em uma tentativa de impedir os efeitos delet&#233;rios do t&#244;nus simp&#225;tico aumentado nos cora&#231;&#245;es de ratos de laborat&#243;rio com anemia ferropriva. Os betabloqueadores, entretanto, falharam na preven&#231;&#227;o da descompensa&#231;&#227;o card&#237;aca naqueles animais<sup>8</sup>.</p>
    <p>A an&#225;lise da VFC &#233; uma t&#233;cnica confi&#225;vel e reprodut&#237;vel para avaliar a atividade auton&#244;mica em pacientes com doen&#231;a cardiovascular. Entretanto, seu uso em pacientes com anemia ferropriva ainda n&#227;o foi totalmente investigado.</p>
    <p>A anemia foi associada com baixa VFC em pacientes ambulatoriais com doen&#231;a card&#237;aca coronariana est&#225;vel<sup>9</sup>. De Chiara e cols.<sup>10</sup> relatou que uma VFC anormal pode representar as primeiras caracter&#237;sticas da doen&#231;a card&#237;aca em pacientes talass&#234;micos, sem evid&#234;ncia de disfun&#231;&#227;o ventricular em exames de rotina. Aytemir e cols.<sup>11</sup> relatou que os par&#226;metros da VFC estavam associados com defici&#234;ncia de vitamina B<sub>12</sub> e que esses par&#226;metros melhoraram com a reposi&#231;&#227;o dessa vitamina em pacientes com defici&#234;ncia de vitamina B<sub>12</sub> e anemia megalobl&#225;stica. Connes e cols.<sup>12</sup> mostraram que a variabilidade global (DPNN, MVFC) e parassimp&#225;tica (PNN50, VQMDP, dom&#237;nio de alta frequ&#234;ncia (AF), os &#237;ndices de VFC eram significantemente mais baixos em indiv&#237;duos portadores de tra&#231;o falciforme e tentaram explicar esse fato como uma adapta&#231;&#227;o fisiol&#243;gica para aumentar a frequ&#234;ncia do batimento card&#237;aco, fornecendo um suprimento adequado de oxig&#234;nio para os tecidos a despeito das altera&#231;&#245;es hemorreol&#243;gicas tais como deformabilidade do eritr&#243;cito e aumento da viscosidade do sangue.</p>
    <p>Em um estudo recente, Yokusoglu e cols.<sup>16</sup> relataram uma defici&#234;ncia nos &#237;ndices globais (DPNN, DPANN) da VFC que poderiam ser causados por um aumento na atividade simp&#225;tica ou diminui&#231;&#227;o na atividade parassimp&#225;tica e uma diminui&#231;&#227;o no PNN50 (um &#237;ndice de atividade parassimp&#225;tica) em anemia ferropriva. Eles sugeriram que a baixa tens&#227;o de oxig&#234;nio nos tecidos com resultante aumento da atividade simp&#225;tica pode ser respons&#225;vel pela altera&#231;&#227;o na fun&#231;&#227;o auton&#244;mica na anemia ferropriva. Em contraste com estudos pr&#233;vios, entretanto, n&#227;o foram observadas diferen&#231;as estatisticamente significantes entre pacientes com anemia ferropriva e o grupo controle saud&#225;vel, exceto pela FC m&#233;dia.</p>
    <p>Entretanto, em nosso estudo, a monitoriza&#231;&#227;o por Holter foi realizada durante uma avalia&#231;&#227;o hospitalar. Portanto, a atividade f&#237;sica de nossos pacientes era limitada; isso se refletiu na m&#233;dia relativamente baixa de FC, quando comparada com os pacientes do estudo de Yokusoglu e cols.<sup>16</sup> (84,4&#177;22,4 bpm vs. 117&#177;19 bpm). Sendo assim, ao combinar nossos resultados com os de estudos pr&#233;vios, podemos concluir que o aumento na atividade f&#237;sica, com o conseq&#252;ente aumento da demanda tecidual de oxig&#234;nio, pode resultar em aumento da atividade simp&#225;tica e diminui&#231;&#227;o da atividade parassimp&#225;tica.</p>
    <p>
      <bold>Limita&#231;&#245;es</bold>
    </p>
    <p>O n&#250;mero de pacientes do estudo &#233; relativamente pequeno para generalizar nossos resultados. N&#227;o fomos capazes de usar par&#226;metros de dom&#237;nio da frequ&#234;ncia da VFC devido &#224; raz&#245;es t&#233;cnicas. Um seguimento teria sido mais informativo. Al&#233;m disso, a reavalia&#231;&#227;o dos par&#226;metros da VFC, ap&#243;s o tratamento da defici&#234;ncia de ferro, poderia ser importante no caso de melhora desses par&#226;metros.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>Em conclus&#227;o, em pacientes com anemia ferropriva com atividade f&#237;sica restrita, a variabilidade da frequ&#234;ncia card&#237;aca n&#227;o se altera, de acordo com nossos resultados. Estudos adicionais, com maior n&#250;mero de pacientes, incluindo dados de seguimento s&#227;o necess&#225;rios para melhor entender o impacto da defici&#234;ncia de ferro no sistema auton&#244;mico e as implica&#231;&#245;es cl&#237;nicas do balan&#231;o auton&#244;mico alterado.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Mustafa Tuncer </p>
        <p> Kazim Karabekir Street </p>
        <p> Yuzuncu Yil University Research Hospital </p>
        <p> Cardiology Department </p>
        <p> 9065100 TURKEY-Van </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="drmtuncer66@yahoo.com">drmtuncer66@yahoo.com</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 19/11/07; revisado recebido em 28/03/08; aceito em 07/04/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Sarnak MJ, Levey    AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as    a risk factor for development of cardiovascular disease: a statement from the    American Heart Association Councils on Kidney in Cardiovascular Disease, High    Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.    Circulation. 2003; 108: 2154-69.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2154</fpage>
          <lpage>69</lpage>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sarnak</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Levey</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Schoolwerth</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Coresh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Culleton</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hamm</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Sarnak MJ, Tighiouart    H, Manjunath G, MacLeod B, Griffith J, Salem D, et al. Anemia as a risk factor    for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC)    study. J Am Coll Cardiol. 2002; 40: 27-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk in Communities (ARIC) study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>27</fpage>
          <lpage>33</lpage>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sarnak</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Tighiouart</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Manjunath</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>MacLeod</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Griffith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Salem</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Task Force of    European Society of Cardiology and the North American Society of Pacing and    Electrophysiology. Heart rate variability, standards of measurement, physiological    interpretation and clinical use. Circulation. 1996; 93: 1043-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart rate variability, standards of measurement, physiological interpretation and clinical use</article-title>
          <source>Circulation</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1043</fpage>
          <lpage>65</lpage>
          <volume>93</volume>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Stein PK, Domitrovich    PP, Kleiger RE, CASR investigators. Including patients with diabetes mellitus    or coronary artery bypass grafting decreases the association between heart rate    variability and mortality after myocardial infarction. Am Heart J. 2004; 147:    309-16.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Including patients with diabetes mellitus or coronary artery bypass grafting decreases the association between heart rate variability and mortality after myocardial infarction</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>309</fpage>
          <lpage>16</lpage>
          <volume>147</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Domitrovich</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Kleiger</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Karcz M, Chojnowska    L, Zareba W, Ruzyllo W. Prognostic significance of heart rate variability in    dilated cardiomyopathy. Int J Cardiol. 2003; 87: 75-81.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic significance of heart rate variability in dilated cardiomyopathy</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>75</fpage>
          <lpage>81</lpage>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Karcz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chojnowska</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zareba</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ruzyllo</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Stein KM, Borer    JS, Hochreiter C, Okin PM, Herrold EM, Devereux RB, et al. Prognostic value    and physiological correlates of heart rate variability in chronic severe mitral    regurgitation. Circulation. 1993; 88: 127-35.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation</article-title>
          <source>Circulation</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>127</fpage>
          <lpage>35</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stein</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hochreiter</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Okin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Herrold</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Anand IS, Kuskowski    MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin    over time related to mortality and morbidity in patients with chronic heart    failure: results from Val-HeFT. Circulation. 2005; 112: 1121-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1121</fpage>
          <lpage>7</lpage>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anand</surname>
              <given-names>IS</given-names>
            </name>
            <name>
              <surname>Kuskowski</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Rector</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Florea</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Glazer</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Hester</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Turner LR, Premo    DA, Gibbs BJ, Hearthway ML, Motsko M, Sappington A, et al. Adaptations to iron    deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling,    and the effect of beta-blockade on cardiac hypertrophy. BMC Physiol. 2002; 2:    1.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy</article-title>
          <source>BMC Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1</fpage>
          <volume>2</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Turner</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Premo</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Gibbs</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Hearthway</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Motsko</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sappington</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Gehi A, Ix J,    Shlipak M, Pipkin SS, Whooley MA. Relation of anemia to low heart rate variability    in patients with coronary heart disease (from the Heart and Soul study). Am    J Cardiol. 2005; 95: 1474-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of anemia to low heart rate variability in patients with coronary heart disease (from the Heart and Soul study)</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1474</fpage>
          <lpage>7</lpage>
          <volume>95</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gehi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ix</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shlipak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pipkin</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Whooley</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. De Chiara B,    Crivellaro W, Sara R, Ruffini L, Parolini M, Fesslova V, et al. Early detection    of cardiac dysfunction in thalassemic patients by radionuclide angiography and    heart rate variability analysis. Eur J Haematol. 2005; 74: 517-22.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Early detection of cardiac dysfunction in thalassemic patients by radionuclide angiography and heart rate variability analysis</article-title>
          <source>Eur J Haematol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>517</fpage>
          <lpage>22</lpage>
          <volume>74</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Chiara</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Crivellaro</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sara</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ruffini</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Parolini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fesslova</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Aytemir K,    Aksoyek S, Buyukas1k Y, Haznedaroglu I, Atalar E, Ozer N. Assessment of autonomic    nervous system functions in patients with vitamin B12 deficiency by power spectral    analysis of heart rate variability. Pacing Clin Electrophysiol. 2000; 23: 975-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of autonomic nervous system functions in patients with vitamin B12 deficiency by power spectral analysis of heart rate variability</article-title>
          <source>Pacing Clin Electrophysiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>975</fpage>
          <lpage>8</lpage>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Aytemir</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aksoyek</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Buyukas1k</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Haznedaroglu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Atalar</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ozer</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Connes P, Martin    C, Barthelemy JC, Monchanin G, Atchou G, Forsuh A, et al. Nocturnal autonomic    nervous system activity impairment in sickle cell trait carriers. Clin Physiol    Funct Imaging. 2006; 26: 87-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Nocturnal autonomic nervous system activity impairment in sickle cell trait carriers</article-title>
          <source>Clin Physiol Funct Imaging</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>87</fpage>
          <lpage>91</lpage>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Connes</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barthelemy</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Monchanin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Atchou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Forsuh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Lee GR. Iron    deficiency and iron-deficiency anemia. In: Lee GR, Bithell TC, Foerster J, Athens    JW, Lukens JN. (eds.). Wintrobe's clinical hematology. 9th ed. Philadelphia:    Lea &amp; Fabiger; 1993. p. 808-10.</mixed-citation>
        <element-citation publication-type="book">
          <source>Wintrobe's clinical hematology</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>808</fpage>
          <lpage>10</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Bithell</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Foerster</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Athens</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Lukens</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Hegde N, Rich    MW, Gayomali C. The cardiomyopathy of iron deficiency. Tex Heart Inst J. 2006;    33: 340-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The cardiomyopathy of iron deficiency</article-title>
          <source>Tex Heart Inst J</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>340</fpage>
          <lpage>4</lpage>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Hegde</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Gayomali</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Petering DH,    Stemmer KL, Lyman S, Krezoski S, Petering HG. Iron deficiency in growing male    rats: a cause of development of cardiomyopathy. Ann Nutr Metab. 1990; 34: 232-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Iron deficiency in growing male rats: a cause of development of cardiomyopathy</article-title>
          <source>Ann Nutr Metab</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>232</fpage>
          <lpage>43</lpage>
          <volume>34</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Petering</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Stemmer</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Lyman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Krezoski</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Petering</surname>
              <given-names>HG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Yokusoglu M,    Nevruz O, Baysan O, Demirkol S, Uzun M, Avcu F, et al. The altered autonomic    nervous system activity in iron deficiency anemia. Tohoku J Exp Med. 2007; 212:    397-402.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The altered autonomic nervous system activity in iron deficiency anemia</article-title>
          <source>Tohoku J Exp Med</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>397</fpage>
          <lpage>402</lpage>
          <volume>212</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yokusoglu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nevruz</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Baysan</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Demirkol</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Uzun</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Avcu</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Heart rate variability in patients with iron deficiency anemia</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Heart rate variability (HRV) is associated with increased cardiac risk factor in several conditions. The iron status of an individual may play an important role in cardiovascular health. OBJECTIVE: To evaluate heart rate variability in patients with iron deficiency anemia. METHODS: Twenty-three patients with iron deficiency anemia (mean hemoglobin (Hb) 8.6&#177;2.2 g/dl) and 10 healthy people (mean Hb 13.9&#177;1.2 g/dl) were assessed with 24-hour ambulatory Holter recordings during in hospital course having limited physical activity. RESULTS: Although mean heart rate was significantly higher in patients with anemia, there was no significant difference regarding HRV parameters compared to the healthy group. CONCLUSION: There was no significant difference in HRV parameters between patients with iron deficiency anemia with limited physical activity and healthy ambulatory people.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart rate</kwd>
        <kwd>anemia, iron-deficiency</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Heart rate variability in patients with iron deficiency anemia</bold>
          </label>
          <p>
            <bold>Mustafa Tuncer<sup>I</sup>; Yilmaz Gunes<sup>I</sup>; Unal Guntekin<sup>I</sup>; Hasan Ali Gumrukcuoglu<sup>I</sup>; Beyhan Eryonucu<sup>I</sup>; Niyazi Guler<sup>I</sup>; Imdat Dilek<sup>II</sup>; Cengiz Demir<sup>II</sup></bold>
          </p>
        </fn>
      </p>
      <p><sup>I</sup>Yuzunci Yil University, Faculty of Medicine, Cardiology Department, Van - Turkey</p>
      <p><sup>II</sup>Yuzunci Yil University, Faculty of Medicine, Hematology Department, Van - Turkey</p>
      <p>Mailing address</p>
      <p>
        <bold>SUMMARY</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Heart rate variability (HRV) is associated with increased cardiac risk factor in several conditions. The iron status of an individual may play an important role in cardiovascular health.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate heart rate variability in patients with iron deficiency anemia.</p>
      <p><bold>METHODS:</bold> Twenty-three patients with iron deficiency anemia (mean hemoglobin (Hb) 8.6&#177;2.2 g/dL) and 10 healthy people (mean Hb 13.9&#177;1.2 g/dL) were assessed with 24-hour ambulatory Holter recordings during in hospital course having limited physical activity.</p>
      <p><bold>RESULTS:</bold> Although mean heart rate was significantly higher in patients with anemia, there was no significant difference regarding HRV parameters compared to the healthy group.</p>
      <p><bold>CONCLUSION:</bold> There was no significant difference in HRV parameters between patients with iron deficiency anemia with limited physical activity and healthy ambulatory people.</p>
      <p><bold>Key words:</bold> Heart rate; anemia, iron-deficiency.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Anemia is an independent risk factor for adverse cardiovascular outcomes in patients with kidney disease<sup>1</sup> and possibly in the general population<sup>2</sup>. Decreased heart rate variability (HRV) is associated with increased mortality and morbidity in various types of heart disease including myocardial infarction, cardiomyopathy, congestive heart failure, and chronic mitral regurgitation<sup>3-7</sup>.</p>
      <p>The iron status of an individual may play an important role in cardiovascular health, as either an excess of iron or iron deficiency may lead to significant problems<sup>8</sup>. It was previously suggested that anemia was associated with low HRV in ambulatory patients with stable coronary heart disease and that low HRV could potentially mediate the association of anemia with increased cardiac risk<sup>9</sup>. Anemia and HRV relation has been searched in several types of anemia; thalassemia<sup>10</sup>, vitamin B<sub>12</sub> deficiency and megaloblastic anemia<sup>11</sup>, sickle cell trait<sup>12</sup>.</p>
      <p>In this study, we aimed at studying the association between HRV parameters and iron deficiency anemia.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>Complete blood count, peripheral blood smear, serum ferritin, serum iron, iron binding capacity and transferrin saturations were examined. The diagnosis of iron deficiency anemia was established as hemoglobin &lt;12 g/dl in women and &lt;13 g/dl in men and serum ferritin &lt;12 ng/ml, mean corpuscular volume (MCV) and mean corpuscular hemoglobin concentration (MCHC) values below the normal range (83 to 97 fl and 32 to 36 g/dl, respectively)<sup>13</sup>.</p>
      <p>With an alpha level of 0.05 and a test power of 0.80, a sample size of 32 participants was considered adequate to define a 15 msec difference in heart rate variability parameters between groups. A total of 23 hospitalized patients diagnosed as having iron deficiency anemia (mean hemoglobin (Hb 8.6&#177;2.2 g/dl) and 10 healthy people (mean Hb 13.9&#177;1.2 g/dl) were enrolled in the study.</p>
      <p>All patients underwent transthoracic echocardiographic examination. Patients with acute bleeding, malignancy, known to have chronic bleeding, thalassemia, sickle cell disease, structural heart disease, diabetes, hypertension, renal failure, hypo- or hyperthyroidism or any other systemic disease were excluded from study. All patients gave written informed consent to the study, and the study was approved by the hospital ethical committee.</p>
      <p>
        <bold>Heart rate variability analysis</bold>
      </p>
      <p>Twenty-four-hour ambulatory electrocardiographic Holter monitoring was performed using a Del Mar Avionics 483 3-channel recorder (Del Mar Medical Systems; Irvine, CA). The recordings were analyzed with a special computer software (Del Mar Holter Analysis System; Del Mar Medical Systems). All recordings were visually examined and manually overread to verify beat classification by an experienced cardiologist. Abnormal beats and areas of artifact were automatically and manually identified and excluded from the analysis. Moreover, the longest and shortest true normal-to-normal intervals were identified for each recording in order to exclude all beats outside this range from the HRV analysis. Intervals within this range were carefully edited.</p>
      <p>The following parameters were used in evaluation of HRV in time domain:</p>
      <p>1) Standard deviation (SD) of all normal-to-normal intervals (SDNN [milliseconds]);</p>
      <p>2) Standard deviations of mean of all normal-to-normal intervals in all consecutive 5-min segments of the entire recording (SDANN [milliseconds]);</p>
      <p>3) the mean square root of differences between adjacent normal-to-normal intervals (MSRSD [milliseconds]);</p>
      <p>4) mean of the SD in all 5-min intervals (HRVM [milliseconds]); and</p>
      <p>5) Standard deviations in all 5-min intervals (SDHRV [milliseconds]).</p>
      <p>
        <bold>Statistics</bold>
      </p>
      <p>Results were expressed as means &#177; SD. Using an SPSS package version 10.0, the data from both groups were compared with Student's t-test for continuous variables and Chi-square test for dichotomous variables, and Mann-Whitney's U-test for variables without normal distribution. A two-tailed p value &lt; 0.05 was considered significant.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>Clinical characteristics and Holter results of the study population are summarized in <xref ref-type="table" rid="t1-body2">Table 1</xref> and <xref ref-type="table" rid="t2-body2">Table 2</xref>. All patients were in sinus rhythm throughout the recordings. No ST-segment changes have been recorded in the overall population. There were no pathologies at the echocardiographic examinations, except for slight valvular regurgitations within the normal limits. The mean heart rate was significantly higher among anemic patients compared to the control group (84.4&#177;22.4 bpm vs. 72.6&#177;13.2 bpm; p=0.005). There was no significant difference between the healthy group and iron-deficient patients in regard to HRV parameters.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt01-en.jpg"/></table-wrap>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt02-en.jpg"/></table-wrap>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>There is increasing evidence that anemia contributes to cardiac disease and death<sup>14,15</sup>. In patients with chronic kidney disease, for instance, anemia is an independent risk factor for the development of cardiovascular disease<sup>1</sup>. In patients with heart failure, anemia is associated with increased morbidity<sup>7</sup>.</p>
      <p>Holter recordings play a pivotal role in identifying arrhythmias; its widely available association with heart rate variability (HRV) analysis provides information about the influences of the autonomic nervous system and sympathovagal balance. Heart rate variability is a method that determines the effects of the autonomic nervous system on the heart and spontaneous changes in heart rate. A decrease in heart rate variability reflects an autonomic dysfunction. Heart rate variability decreases after MI, as well as in diabetic neuropathy and heart failure. Currently, HRV is considered a predictor of sudden cardiac arrest and arrhythmias<sup>3-6</sup>.</p>
      <p>Iron deficiency is the most common nutritional deficiency in developed and developing regions of the world. The physiologic response to anemia is a compensatory increase in cardiac output through increases in blood volume, preload, heart rate, and stroke volume, along with a decrease in afterload. Therefore, the increased sympathetic activity, evidenced as palpitation and tachycardia, is frequent in patients with anemia<sup>13</sup>.</p>
      <p>An extreme result of iron deficiency is cardiomyopathy. The pathogenesis of cardiomyopathy associated with anemia has not been ascertained. Several hypotheses have been advanced to explain how iron-deficiency anemia causes cardiomyopathy. It has been suggested that, similarly to other types of heart failure, high-output heart failure is driven by ongoing increased sympathetic nervous activity. In order to test this hypothesis, one study used &#946;-blockade in an attempt to blunt the deleterious effect of the elevated sympathetic tone on the hearts of iron-deficient laboratory rats. &#946;-Blockers, however, failed to prevent cardiac decompensation in those animals<sup>8</sup>.</p>
      <p>The analysis of heart rate variability (HRV) is a reliable and reproducible technique for assessing autonomic activity in patients with cardiovascular disease. However, its use in patients with iron deficiency anemia has not been investigated thoroughly.</p>
      <p>Anemia was associated with low HRV in ambulatory patients with stable coronary heart disease<sup>9</sup>. De Chiara et al<sup>10</sup> reported that abnormal HRV might represent the early features of cardiac disease in thalassemic patients with no evidence of ventricular dysfunction at routine evaluation. Aytemir et al<sup>11</sup> reported that HRV parameters were associated with vitamin B<sub>12</sub> deficiency and parameters were improved with vitamin B<sub>12</sub> replacement in patients with vitamin B<sub>12</sub> deficiency and megaloblastic anemia. Connes et al<sup>12</sup> showed that global variability (SDNN, HRVM) and parasympathetic (PNN50, MSRSD, high frequency domain (HF)) HRV indices were significantly lower in the sickle cell trait carriers and tried to explain this fact as a physiological adaptation to increase heart beat frequency, providing adequate O<sub>2</sub> supplies to tissues despite the hemorheological alterations such as red blood cell deformability and increased blood viscosity.</p>
      <p>In a recent study Yokusoglu et al<sup>16</sup> reported an impairment in global (SDNN, SDANN) HRV indices that might be caused by increased sympathetic or decreased parasympathetic activity and decreased PNN50 (a parasympathetic activity index) in iron deficiency anemia. They suggested that low oxygen tension in tissues with resultant increased sympathetic activity may be responsible for altered autonomic function in iron deficiency anemia. In contrast to previous studies, however, no statistically significant differences were observed between iron-deficient anemia patients and the healthy control group, except for mean heart rate. However, in our study, Holter monitoring was carried out during an in-hospital evaluation. Therefore, physical activity of the patients were limited, reflected by relatively lower mean heart rate compared to the study patients of Yokusoglu et al<sup>16</sup> (84.4&#177;22.4 bpm vs. 117&#177;19 bpm). Therefore, combining our results with previous studies, it can be concluded that the increase in physical activity with consequent increase in tissue O<sub>2</sub> demand may result in increased sympathetic and decreased parasympathetic activity.</p>
      <p>
        <bold>Limitations</bold>
      </p>
      <p>The sample size of the present study is relatively small to generalize our results. We were not able to use frequency domain parameters of HRV due to technical reasons. A follow-up would have been more informative. Furthermore, the reevaluation of HRV parameters after treatment of iron deficiency might have been meaningful in case of improvement of the HRV parameters.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>In conclusion, in patients with iron deficiency anemia with restricted physical activity, heart rate variability does not change according to our results. Further and larger studies including follow-up data are needed to better understand the impact of iron deficiency on the autonomic system and the clinical implications of altered autonomic balance.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Variabilidad de la frecuencia cardiaca en pacientes con anemia ferropriva</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La variabilidad de la frecuencia cardiaca (VFC) est&#225; asociada al aumento del factor de riesgo cardiaco en varias condiciones. Las concentraciones de hierro presentadas por un individuo pueden ejercer un rol importante para la salud cardiovascular. OBJETIVO: Evaluar la VFC en pacientes con anemia ferropriva. M&#201;TODOS: Se evaluaron a 23 pacientes con anemia ferropriva (hemoglobina [Hb] media = 8,6&#177;2,2 g/dL) y a 10 individuos sanos (Hb media = 13,9&#177;1,2 g/dL) por medio de monitoreo ambulatorio por 24 horas (Sistema Holter) durante estad&#237;a hospitalaria con actividad f&#237;sica limitada. RESULTADOS: Aunque la frecuencia cardiaca (FC) media fue significantemente m&#225;s alta en pacientes con anemia, no hubo diferencia significante respecto a los par&#225;metros de la VFC en comparaci&#243;n con el grupo de individuos sanos. CONCLUSIONES: No hay diferencia significante en los par&#225;metros de la VFC entre pacientes con anemia ferropriva e individuos sanos.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Frecuencia cardiaca</kwd>
        <kwd>anemia ferropriva</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p><undefined id="top-body3"/>Variabilidad de la frecuencia cardiaca en pacientes con anemia ferropriva</p>
      <p>
        <bold>Mustafa Tuncer<sup>I</sup>; Yilmaz Gunes<sup>I</sup>; Unal Guntekin<sup>I</sup>; Hasan Ali Gumrukcuoglu<sup>I</sup>; Beyhan Eryonucu<sup>I</sup>; Niyazi Guler<sup>I</sup>; Imdat Dilek<sup>II</sup>; Cengiz Demir<sup>II</sup></bold>
      </p>
      <p><sup>I</sup>Universidade Yuzunci Yil, Faculdade de Medicina, Departamento de Cardiologia, Van - Turquia</p>
      <p><sup>II</sup>Universidade Yuzunci Yil, Faculdade de Medicina, Departamento de Hematologia, Van - Turquia</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La variabilidad de la frecuencia cardiaca (VFC) est&#225; asociada al aumento del factor de riesgo cardiaco en varias condiciones. Las concentraciones de hierro presentadas por un individuo pueden ejercer un rol importante para la salud cardiovascular.</p>
      <p><bold>OBJETIVO: </bold> Evaluar la VFC en pacientes con anemia ferropriva.</p>
      <p><bold>M&#201;TODOS: </bold> Se evaluaron a 23 pacientes con anemia ferropriva (hemoglobina [Hb] media = 8,6&#177;2,2 g/dL) y a 10 individuos sanos (Hb media = 13,9&#177;1,2 g/dL) por medio de monitoreo ambulatorio por 24 horas (Sistema Holter) durante estad&#237;a hospitalaria con actividad f&#237;sica limitada.</p>
      <p><bold>RESULTADOS: </bold> Aunque la frecuencia cardiaca (FC) media fue significantemente m&#225;s alta en pacientes con anemia, no hubo diferencia significante respecto a los par&#225;metros de la VFC en comparaci&#243;n con el grupo de individuos sanos.</p>
      <p><bold>CONCLUSIONES: </bold> No hay diferencia significante en los par&#225;metros de la VFC entre pacientes con anemia ferropriva e individuos sanos.</p>
      <p><bold>Palabras clave: </bold> Frecuencia cardiaca, anemia ferropriva.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La anemia es un factor de riesgo independiente para resultados cardiovasculares adversos en pacientes con enfermedad renal<sup>1</sup> y, posiblemente, en la poblaci&#243;n en general<sup>2</sup>. Una disminuci&#243;n en la variabilidad de la frecuencia cardiaca (VFC) est&#225; asociada al aumento de la mortalidad y morbidad en varias formas de enfermedad cardiaca, incluso el infarto de miocardio, la cardiomiopat&#237;a, la insuficiencia cardiaca congestiva (ICC) y la regurgitaci&#243;n mitral cr&#243;nica<sup>3-7</sup>.</p>
      <p>Los niveles de hierro de un individuo pueden ejercer un rol importante en la salud cardiovascular, si se considera que el exceso o la deficiencia de hierro pueden provocar problemas significativos<sup>8</sup>. Ya se sugiri&#243; que existe asociaci&#243;n entre anemia y baja VFC en pacientes ambulatorios con enfermedad cardiaca coronaria estable; del mismo modo, ya se indic&#243; que la baja VFC podr&#237;a potencialmente mediar la asociaci&#243;n de la anemia con el aumento del riesgo cardiaco<sup>9</sup>. La asociaci&#243;n con VFC ha sido estudiada en diversos tipos de anemia, tales como talasemia<sup>10</sup>, deficiencia de vitamina B<sub>12</sub> y anemia megalobl&#225;stca<sup>11</sup>, as&#237; como tambi&#233;n anemia falciforme<sup>12</sup>.</p>
      <p>El objetivo del presente estudio fue analizar la asociaci&#243;n entre par&#225;metros de VFC y anemia ferropriva.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>Se examinaron hemograma completo, frotis de sangre perif&#233;rica, ferritina s&#233;rica, hierro s&#233;rico, capacidad de enlace del hierro y saturaci&#243;n de transferrina. Como diagn&#243;stico de anemia ferropriva se establecieron niveles de hemoglobina &lt; 12 g/dL en mujeres y &lt; 13 g/dL en varones; ferritina s&#233;rica &lt; 12 ng/mL; y valores de volumen corpuscular medio (VCM) y concentraci&#243;n media de hemoglobina corpuscular (CMHC) abajo de la franja normal (83-97 fL y 32-36 g/dL, respectivamente)<sup>13</sup>.</p>
      <p>Con un nivel alfa de 0,05 y poder de prueba de 0,80, se consider&#243; adecuada una muestra con 32 participantes para definir una diferencia de 15 ms en la VFC entre los grupos. Un total de 23 pacientes hospitalizados, diagnosticados con anemia ferropriva (hemoglobina [Hb] media: 8,6&#177;2,2 g/dL) y se incluyeron en el estudio otras 10 personas sanas. Todos los pacientes fueron sometidos a la ecocardiograf&#237;a transtor&#225;cica. Por otra parte, se excluyeron del estudio, a pacientes con sangrado agudo, malignidades, sangrado cr&#243;nico conocido, talasemia, enfermedad falciforme, enfermedad cardiaca estructural, diabetes, hipertensi&#243;n, insuficiencia renal, hipo o hipertiroidismo, o, a&#250;n, cualquier otra enfermedad sist&#233;mica. Todos los pacientes firmaron el formulario de consentimiento informado; el Comit&#233; de &#201;tica del hospital aprob&#243; este estudio.</p>
      <p>
        <bold>An&#225;lisis de la variabilidad de frecuencia cardiaca</bold>
      </p>
      <p>Se realiz&#243; monitoreo ambulatorio electrocardiogr&#225;fico de 24 horas, por medio del sistema Holter, con la utilizaci&#243;n de un aparato grabador Del Mar Avionics 483 de 3 canales (Del Mar Medical Systems; Irvine, CA). Se analizaron los registros con un software especial (Del Mar Holter Analysis System; Del Mar Medical Systems). Se examinaron visualmente todos los registros; enseguida, un cardi&#243;logo con experiencia los ley&#243; manualmente para verificar la clasificaci&#243;n del latido. Se identificaron y excluyeron del an&#225;lisis -tanto autom&#225;tica como manualmente- los latidos anormales y &#225;reas de artefacto. Adem&#225;s de ello, para cada registro se identificaron los intervalos NN ("<italic>normal to normal</italic>", del ingl&#233;s) verdaderos m&#225;s largos y m&#225;s cortos a fin de excluir todos los latidos fuera de esa franja del an&#225;lisis de VFC. Los intervalos dentro de la franja se editaron cuidadosamente.</p>
      <p>Se utilizaron los siguientes par&#225;metros en la evaluaci&#243;n de la VFC en el dominio tiempo:</p>
      <p>1) desviaci&#243;n est&#225;ndar (DE) de todos os intervalos NN (DENN);</p>
      <p>(2) DE del promedio de todos los intervalos NN en todos los segmentos de 5 minutos consecutivos del total grabado (DETNN) [milisegundos];</p>
      <p>3) valor cuadr&#225;tico medio de las diferencias entre intervalos NN adyacentes (VQMEP) [milisegundos];</p>
      <p>4) promedio de la desviaci&#243;n est&#225;ndar en todos los intervalos de 5 minutos (MVFC) [milisegundos]; y, por &#250;ltimo</p>
      <p>5), desviaci&#243;n est&#225;ndar en todos los intervalos de 5 minutos (DEVFC) [milisegundos].</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Se expresan los resultados en forma de promedio y DE. Con auxilio del software SPSS versi&#243;n 10.0, se compararon los dados de los grupos a trav&#233;s de la prueba <italic>t</italic> de Student para variables continuas, prueba del Chi-cuadrado para variables dicot&#243;micas y Prueba U de Mann-Whitney para variables sin distribuci&#243;n normal. Se consider&#243; significante un p-valor de dos colas &lt; 0,05.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>En las <xref ref-type="table" rid="t1-body3">Tablas 1</xref> y <xref ref-type="table" rid="t2-body3">2</xref> est&#225;n resumidas las caracter&#237;sticas cl&#237;nicas del Holter de 24 horas de la poblaci&#243;n estudiada. Todos los pacientes estaban en ritmo sinusal durante los registros. No se registr&#243; ninguna alteraci&#243;n de segmento ST en la poblaci&#243;n en general. Tampoco se observaron patolog&#237;as en el examen ecocardiogr&#225;fico, excepto por leve regurgitaci&#243;n valvular dentro de los l&#237;mites normales. La frecuencia cardiaca (FC) media se mostraba significantemente m&#225;s alta en pacientes an&#233;micos, si comparados al grupo control (84,4&#177;22,4 lpm vs. 72,6&#177;13,2 lpm; p=0,005). No hubo diferencia significante entre el grupo sano y los pacientes con deficiencia de hierro con respecto a los par&#225;metros de VFC.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt01-es.jpg"/></table-wrap>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-92-05-0400-00011-gt02-es.jpg"/></table-wrap>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>Hay un aumento de las evidencias de que la anemia contribuye para la enfermedad cardiaca y la muerte<sup>14,15</sup>. En pacientes con enfermedad renal cr&#243;nica, por ejemplo, la anemia constituye un factor de riesgo independiente para el desarrollo de enfermedad cardiovascular<sup>1</sup>. En pacientes con insuficiencia cardiaca (IC), la anemia se asocia con el aumento de la morbidad<sup>7</sup>.</p>
      <p>Los registros de monitoreo por Holter ejercen un rol esencial en la identificaci&#243;n de arritmias; su asociaci&#243;n con el an&#225;lisis de la VFC -ampliamente utilizada- suministra informaciones sobre las influencias del sistema nervioso aut&#243;nomo (SNA), as&#237; como del balance simp&#225;tico-vagal. La VFC es un m&#233;todo que determina los efectos del SNA sobre el coraz&#243;n y los cambios espont&#225;neos en la frecuencia cardiaca. La disminuci&#243;n en la variabilidad de la frecuencia cardiaca refleja una disfunci&#243;n auton&#243;mica. La VFC disminuye tanto tras IM, como en presencia de neuropat&#237;a diab&#233;tica e IC. Actualmente, se considera la VFC como un predictor de paro cardiaco s&#250;bito y arritmias<sup>3-6</sup>.</p>
      <p>La deficiencia de hierro es la carencia nutricional m&#225;s com&#250;n en las regiones desarrolladas y en las en desarrollo del mundo. La respuesta fisiol&#243;gica a la anemia se revela en un incremento compensatorio del gasto cardiaco a trav&#233;s de aumentos en el volumen de sangre, precarga, FC y volumen de derrame, acompa&#241;ada de una disminuci&#243;n en la postcarga. De ese modo, el aumento en la actividad simp&#225;tica, que se refleja en forma de palpitaci&#243;n y taquicardia, resulta frecuente en pacientes con anemia<sup>13</sup>.</p>
      <p>La cardiomiopat&#237;a representa un resultado extremo de la deficiencia de hierro. Todav&#237;a no se confirm&#243; la patog&#233;nesis de la cardiomiopat&#237;a asociada con anemia. Varias hip&#243;tesis han sido propuestas para explicar c&#243;mo la anemia ferropriva causa la cardiomiopat&#237;a. Se sugiere que, as&#237; como en otros tipos de IC, el incremento continuo de la actividad nerviosa simp&#225;tica sea responsable del desarrollo de insuficiencia cardiaca de alto gasto. Para probar esa hip&#243;tesis, un estudio utiliz&#243; betabloqueo en un intento de impedir los efectos letales del tono simp&#225;tico aumentado en los corazones de ratas de laboratorio con anemia ferropriva. Los betabloqueantes, sin embargo, fallaron en prevenir la descompensaci&#243;n cardiaca de aquellos animales<sup>8</sup>.</p>
      <p>El an&#225;lisis de la VFC representa una t&#233;cnica confiable y reproducible para evaluar la actividad auton&#243;mica en pacientes con enfermedad cardiovascular. No obstante, todav&#237;a no se investig&#243; totalmente su utilizaci&#243;n en pacientes con anemia ferropriva.</p>
      <p>La anemia se asoci&#243; con baja VFC en pacientes ambulatorios con enfermedad cardiaca coronaria estable<sup>9</sup>. De Chiara et al.<sup>10</sup> relataron que una VFC anormal puede representar las primeras caracter&#237;sticas de la enfermedad cardiaca en pacientes talas&#233;micos sin evidencia de disfunci&#243;n ventricular en ex&#225;menes de rutina. Aytemir et al.<sup>11</sup>, a su vez, relataron que los par&#225;metros de la VFC se asociaban con deficiencia de vitamina B<sub>12</sub>, y que dichos par&#225;metros mejoraron con la reposici&#243;n de esa vitamina en pacientes que presentaban deficiencia de vitamina B<sub>12</sub> y anemia megalobl&#225;stica. Connes et al.<sup>12</sup> demostraron que la variabilidad global (DENN, MVFC) y parasimp&#225;tica (PNN50, VQMDE, dominio de alta frecuencia [AF]), los indicadores de VFC se mostraban significantemente m&#225;s bajos en individuos portadores de anemia falciforme; dicho estudio intent&#243; explicar ese hecho como una adaptaci&#243;n fisiol&#243;gica para aumentar la frecuencia del latido cardiaco, al suministrar un suplemento adecuado de ox&#237;geno para los tejidos a pesar de las alteraciones hemorreol&#243;gicas, tales como deformabilidad del eritrocito y aumento de la viscosidad de la sangre.</p>
      <p>En un estudio reciente, Yokusoglu et al.<sup>16</sup> verificaron una deficiencia en los indicadores &#237;ndices globales (DENN, DEANN) de la VFC que podr&#237;a tener como causa un aumento en la actividad simp&#225;tica o disminuci&#243;n tanto en la actividad parasimp&#225;tica como en el PNN50 (un indicador de actividad parasimp&#225;tica) en presencia de anemia ferropriva. Ellos sugirieron que la baja tensi&#243;n de ox&#237;geno en los tejidos, con consecuente aumento de la actividad simp&#225;tica puede ser responsable de la alteraci&#243;n en la funci&#243;n auton&#243;mica en la anemia ferropriva. Sin embargo, en contraste con estudios previos, no se observaron diferencias estad&#237;sticamente significantes entre pacientes con anemia ferropriva y el grupo control sano, excepto por la FC media.</p>
      <p>Ya en nuestro estudio, se realiz&#243; el monitoreo por Holter durante una evaluaci&#243;n hospitalaria. Por tanto, la actividad f&#237;sica de nuestros pacientes era limitada; ello se reflej&#243; en la media relativamente baja de FC, cuando comparada con los pacientes del estudio de Yokusoglu et al.<sup>16</sup> (84,4&#177;22,4 lpm vs. 117&#177;19 lpm). As&#237;, al combinar nuestros resultados con los de estudios previos, podemos concluir que el aumento en la actividad f&#237;sica -con el consecuente incremento de la demanda tisular de ox&#237;geno- puede implicar no s&#243;lo en aumento de la actividad simp&#225;tica como tambi&#233;n en disminuci&#243;n de la actividad parasimp&#225;tica.</p>
      <p>
        <bold>Limitaciones</bold>
      </p>
      <p>El n&#250;mero de pacientes del estudio resulta relativamente peque&#241;o para generalizar nuestros resultados. No fuimos capaces de usar par&#225;metros de dominio de la frecuencia de la VFC en virtud de razones t&#233;cnicas. Un seguimiento habr&#237;a sido m&#225;s informativo. Adem&#225;s de ello, la reevaluaci&#243;n de los par&#225;metros de la VFC, tras el tratamiento de la deficiencia de hierro, podr&#237;a mostrarse importante en el caso de mejor&#237;a de los mismos par&#225;metros.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>Concluimos que en pacientes con anemia ferropriva con actividad f&#237;sica restricta, la variabilidad de la frecuencia cardiaca no se altera, de acuerdo con nuestros resultados. Estudios adicionales, con mayor n&#250;mero de pacientes, y que incluyan datos de seguimiento, resultan necesarios para mejor comprender el impacto de la deficiencia de hierro en el sistema auton&#243;mico, as&#237; como las implicaciones cl&#237;nicas del balance auton&#243;mico alterado.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
